Search company, investor...

Gordagen Pharmaceuticals


Series A | Alive

Total Raised




Last Raised

$5.33M | 9 yrs ago

About Gordagen Pharmaceuticals

Gordagen Pharmaceuticals is working to deliver a range of safe, natural and clinically proven nutraceutical and pharmaceutical products to initially support the heart health, diabetes and fitness health markets.

Headquarters Location

90 Queensbridge Street

Southbank, Victoria, 3006,


+61 (0) 412 193 350

Missing: Gordagen Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Gordagen Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Gordagen Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Gordagen Pharmaceuticals is included in 3 Expert Collections, including Vitamin & Supplement Startups.


Vitamin & Supplement Startups

662 items


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



1,904 items

Gordagen Pharmaceuticals Patents

Gordagen Pharmaceuticals has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Vegetable oils, Nutrition, Phenols, Transcription factors, Cooking oils


Application Date


Grant Date



Related Topics

Vegetable oils, Nutrition, Phenols, Transcription factors, Cooking oils



Latest Gordagen Pharmaceuticals News

Gordagen Pharmaceuticals Attends ECRM and Makes Big Splash

Jul 21, 2016

Retailers Showed Serious Interest in the Brand BOCA RATON, FL--(Marketwired - July 21, 2016) - Gordagen Pharmaceuticals, a company dedicated to developing high-quality nutraceuticals and prescription medicines based on natural tocotrienols (T3), announced the company was successful in forging some important new connections for its nE1-Heart™ brand when it attended the 2016 ECRM Diet, Vitamin & Sports Nutrition conference in Tampa, Florida. Gordagen will launch its first supplement product nE1-Heart™ (anyone heart) during the next quarter, making this specific ECRM event a pivotal opportunity to develop distribution channels. "This event gave our brand the opportunity to meet with some of the industry's heavy hitters in Walgreens, Vitamin Shoppe, Vitamin World, CVS, Cardinal Health, and AmeriMark," said Dr. Glenn Tong, the Managing Director and CEO of Gordagen Pharmaceuticals. "These connections will be vital as we launch nE1-Heart, into the significant US supplement market -- with possible sales opportunities for Gordagen Pharmaceuticals. " The ECRM event gives companies in the nutritional, sports and health fields a chance to gather together and meet with some of the most influential retail buyers in their respective industries. Sales executives report outstanding performance at the event, and are very positive about their future coming out of it. Dr. Glenn Tong and Dr. Michael Mathai, an Associate Professor of sports and nutrition physiology at the Victoria University in Australia founded the company in Melbourne, Australia in 2012. Its specific focus is targeting heart health, exercise endurance and muscle recovery after exercise. The natural therapeutic potential of T3 is at the core of Gordagen's products, which are set to debut soon in the United States. The benefits of T3 have been largely unexplored and unrecognized until recently because of the difficulty associated with finding sufficient amounts of alpha-, delta- and gamma-isomers of T3 and because of the variables and relatively poor absorption levels of T3 in the body. This poor absorption exists because the primary component of vitamin E, tocopherols, competes with T3s in the liver and because of the way digestion in the gut and metabolism in the liver occurs. Gordagen's products make use of its proprietary melt-delivery MELT3™ technology, which has been shown in the company's own clinical studies to have very good bioavailability. This solves the poor absorption problem and ensures adequate amounts of T3 are sent out to the targeted tissues throughout the body. Gordagen's very first supplement product is nE1-Heart™ (anyone heart), which is geared toward people over 40 years old, or simply anyone interested in maintaining good heart and general cardiovascular health. Clinical and animal studies that have been published in scientific journals that demonstrate the dietary ingredients in the product, delta and gamma tocotrienols, promote the maintenance of normal cholesterol levels in people who are already within the normal range. "It was extremely important to be involved in the ECRM trade show, and we're very excited about the opportunities we have in store from it," said Dr. Tong. For more information about Gordagen Pharmaceuticals and its products, visit the company's website at . Contact Information

Gordagen Pharmaceuticals Frequently Asked Questions (FAQ)

  • Where is Gordagen Pharmaceuticals's headquarters?

    Gordagen Pharmaceuticals's headquarters is located at 90 Queensbridge Street, Southbank.

  • What is Gordagen Pharmaceuticals's latest funding round?

    Gordagen Pharmaceuticals's latest funding round is Series A.

  • How much did Gordagen Pharmaceuticals raise?

    Gordagen Pharmaceuticals raised a total of $5.33M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.